New Protocol: Lurbinectedin + Atezolizumab for First-Line SCLC Maintenance

  • Study

    Randomized, multicentre, open-label, phase 3 trial [IMforte]
    First-line maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC)
    Lurbinectedin plus atezolizumab (n=242) vs atezolizumab (n=241) every 3 weeks

  • Efficacy

    Progression-free survival: 5.4 mos vs 2.1 mos (HR 0.54 [0.43-0.67])
    Overall survival: 13.2 mos vs 10.6 mos (HR 0.73 [0.57-0.95])

  • Safety

    Grade >=3 AEs: anaemia (8% vs 1%), decreased neutrophil count (7% vs 0%), decreased platelet count (7% vs 0%)
    Serious AEs: 31% vs 17%
    Treatment discontinuation: 6% vs 3%


    • Lancet Oncol. Published online June 2, 2025

    Paz-Ares L,Borghaei H,Liu SV Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

    http://doi.org/10.1016/S0140-6736(25)01011-6

    Reviewed by Elvin Chalabiyev, MD on Sep 3, 2025

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag